Imunon Inc
Research Imunon Inc (IMNN) on Bullrun: market cap USD 6.51M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMNN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.51M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 4.25M
- Free cash flow-USD 15.06M
Valuation Snapshot
latest market cap is USD 6.51M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | USD 14.50M | -USD 14.18M | n/a | -6.83 | USD 8.78M | USD 1.01M | USD 7.06M |
| FY2024 | USD 0 | -USD 18.62M | -USD 18.88M | n/a | -16.94 | USD 5.87M | USD 1.14M | USD 4.24M |
| FY2023 | n/a | -USD 19.51M | -USD 19.47M | n/a | -2.16 | USD 5.84M | USD 1.62M | USD 13.39M |
| FY2022 | USD 500.00K | -USD 35.90M | -USD 23.36M | n/a | -5.03 | USD 11.49M | USD 5.96M | USD 29.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.51M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.08M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 11.98M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 5.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 8.73M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 40.64M | n/a | n/a | n/a |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Imunon Inc's market cap?
Imunon Inc's market capitalization is USD 6.51M.
What does Imunon Inc do?
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.